MDMA-Assisted Psychotherapy Improves PTSD

By |2018-06-05T15:12:24-07:00June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

An Alzheimer’s Antibiotic Receives Initial Funding

By |2018-06-01T09:11:54-07:00June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]

Latest Research on Cannabis and Cannabidiols: Autism, Stress Anxiety and Depression

By |2019-03-28T18:53:46-07:00April 30th, 2018|Featured, We Know Psychiatry|

Autism Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder (ASD). The study, scheduled to launch [...]

Title

Go to Top